Drug intelligence / Profile preview

RV3131A-HC3221

Development stage: Unknown
Lead developer: Pierre Fabre Dermatologie
Modality: Small Molecules
Administration: Topical

Overview

RV3131A-HC3221 is an investigational topical sunscreen formulation developed by Pierre Fabre Dermatologie (Institut de Recherche Pierre Fabre) specifically for the prevention of polymorphic light eruption (PMLE). PMLE is a common immune-mediated skin reaction to ultraviolet (UV) radiation, characterized by itchy rashes or blisters following sun exposure. RV3131A-HC3221 acts as a broad-spectrum photoprotective agent, utilizing a combination of UV filters to prevent the induction of skin lesions by blocking UVA and UVB radiation. The formulation has been evaluated in Phase 2 clinical trials in Europe to determine its efficacy and optimal dosing in adults with a history of PMLE confirmed by photobiologic testing.

Beyond the preview

Go deeper on RV3131A-HC3221.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RV3131A-HC3221.

Explore the full profile